Abstract:The presence of EGFR activating mutations and ALK chromosomic rearrangements with corresponding tyrosine kinase inhibitors (TKIs) has revolutionized the treatment strategies of patients with non-small cell lung cancer (NSCLC). Although tremendously initial response and manageable toxicity profiles, acquired resistance inevitably develops after approximately 1 year treatment with EGFR-TKIs (erlotinib and gefitinib) and ALK inhibitor (crizotinib). Encouragingly, third-generation EGFR-TKIs including AZD9291, CO1686 and brigatinib have showed striking efficacy overcoming acquired resistance driven by T790M secondary mutations. Other novel third-generation EGFR-TKIs such as ASP8274, EGF816, PF-06747775 and avitinib are also being investigated in early-stage clinical trials and the survival and safety data will be released in the near future. Another promising novel EGFR-TKI, namely AZD3759 has showed promising response in patients with brain metastases and leptomeningeal disease. Recently, EAI045, an EGFR allosteric inhibitor, in combination with cetuxmab exhibit antitumor activity in mouse models of lung cancer driven by L858R/T790M/C797S, a resistant mutation of AZD9291. Meanwhile, second-generation ALK inhibitors (ceritinib and alectinib) have entered clinical applications for NSCLC patients with ALK rearrangements after failure of crizotinib and third-generation ALK inhibitors (lorlatinib and ASP3026) are also being evaluated in clinical trials overcoming known ALK resistant mutations. On the other hand, with the development of high-throughput sequencing, called next-generation sequencing (NGS) and genomic technologies, more novel molecular targets such as MET 14 exon skipping splicing mutations have been identified as potential therapeutic targets and simultaneously analyzing hundreds of molecular alterations have turned out reality with limited tumor tissues. In the recent years, the emergence of numbers of oncogenic drivers other than EGFR mutations and ALK rearrangements has divided NSCLC into multiple distinct subtypes amenable to corresponding targeted therapy. For instance, dabrafenib either as monotherapy or in combination with MEK inhibitor (trametinib) has displayed promising antitumor activity and manageable safety profile in patients with BRAF V600E mutations, accounting for around 1.4% of patients with NSCLC. Other novel molecular targets maybe serving as oncogenic drivers including mutations in HER2 (neratinib and pyrotinib) and PI3KCA (BKM120 and GDC0941), ROS1 (entrectinib, foretinib and lorlatinib), RET (XL184) and NTRK (entrectinib) rearrangements and FGFR1 gene amplification (AZD4547, Lenvatinib and FP-1039) are being evaluated either in preclinical settings or early-stage clinical trials. Section not applicable Section not applicable Section not applicable

Clinical Features and Therapeutic Options in Non‐small Cell Lung Cancer Patients with Concomitant Mutations of EGFR, ALK, ROS1, KRAS or BRAF

Concomitant Mutation Status of ALK-rearranged Non-Small Cell Lung Cancers and Its Prognostic Impact on Patients Treated with Crizotinib

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma

Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation

PUB007 Novel TKIs in Non-Small Cell Lung Cancer

Comprehensive Investigation of Oncogenic Driver Mutations in Chinese Non-Small Cell Lung Cancer Patients.

Concurrent Gene Alterations with EGFR Mutation and Treatment Efficacy of EGFR-TKIs in Chinese Patients with Non-Small Cell Lung Cancer

Characterization of Distinct Types of KRAS Mutation and Its Impact on First-Line Platinum-Based Chemotherapy in Chinese Patients with Advanced Non-Small Cell Lung Cancer

Uncommon EGFR Mutations in a Cohort of Chinese NSCLC Patients and Outcomes of First-Line EGFR-TKIs and Platinum-Based Chemotherapy.

[The Concomitant Gene Alterations Impact the Therapeutic Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Sensitive Mutation].

Concurrent Classic Driver Oncogenes Mutation with ROS1 Rearrangement Predicts Superior Clinical Outcome in NSCLC Patients.

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.

Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome

Concurrent Oncogene Mutation Profile in Chinese Patients with Stage Ib Lung Adenocarcinoma.

Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations

P2.01-117 Concurrent Gene Alterations in Treatment-Naïve EGFR-Mutant Advanced Non-Small Cell Lung Cancer

Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

Driver Gene Alterations Profiling of Chinese Non‐small Cell Lung Cancer and the Effects of Co‐occurring Alterations on Immunotherapy